The French beauty leader is committed to integrating digital into the heart of its business and recognizes that infusions from external innovators are vital to keeping the system pumping. The firm’s investment in a tech- and digital-focused fund managed by Partech Ventures will connect it with startup technologies and services “that can transform people’s relationship to beauty.”
L’Oreal S.A. expects its investment in an early-stage Partech Ventures fund to plug it into emerging digital innovations at the startup level, keeping the French beauty giant at the forefront of trends in the sector.
Announced Dec. 27, the partnership with Paris-based venture capital firm Partech “will help L’Oreal tap into innovations and services that...
Curve Biosciences has developed a "Whole-Body Intelligence" platform using cfDNA from blood to monitor chronic diseases, starting with the liver. Focused on liver cirrhosis and MASH, the company aims to aid in treatment decisions and plans to expand into monitoring other organs.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
L’Oréal and Galderma have signed a memorandum of understanding to collaborate on complementary research projects to discover ‘new avenues and accelerate innovation’ in the field of dermatology. L’Oreal has arranged to purchase a 10% stake in its partner.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
